Curis logo

CurisNASDAQ: CRIS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

01 August 2000

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$24.63 M
-75%vs. 3y high
26%vs. sector
-vs. 3y high
-vs. sector
-35.49
-435%vs. 3y high
2%vs. sector
-76%vs. 3y high
42%vs. sector

Price

after hours | Mon, 04 Nov 2024 22:06:20 GMT
$4.12-$0.14(-3.29%)

Dividend

No data over the past 3 years
$2.55 M$2.28 M
$2.55 M-$11.80 M

Analysts recommendations

Institutional Ownership

CRIS Latest News

Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer
prnewswire.com23 September 2024 Sentiment: POSITIVE

Symposium hosted by Eric S. Winer, MD, and Grzegorz S.

Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference
prnewswire.com17 September 2024 Sentiment: POSITIVE

LEXINGTON, Mass. , Sept. 17, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference later today at 4:15 PM ET.

Curis to Present at Upcoming Healthcare Conferences in September
prnewswire.com04 September 2024 Sentiment: POSITIVE

LEXINGTON, Mass. , Sept. 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The H.C.

Curis Provides Second Quarter 2024 Financial and Operating Update
prnewswire.com01 August 2024 Sentiment: POSITIVE

EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass.

Curis to Present at Upcoming Healthcare Conference in July
prnewswire.com10 July 2024 Sentiment: POSITIVE

LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the Jones Healthcare Seaside Summit 2024 on July 15, 2024 at 8:00 a.m.

What Makes Curis (CRIS) a New Buy Stock
zacks.com09 July 2024 Sentiment: POSITIVE

Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com08 July 2024 Sentiment: POSITIVE

LEXINGTON, Mass. , July 8, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on July 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 25,000 shares of Curis common stock to a new employee, with a grant date of July 1, 2024 (the "Q3 2024 Inducement Grant").

Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
Zacks Investment Research05 April 2024 Sentiment: POSITIVE

Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Curis's stock rises as analysts see ‘the next Pharmacyclics'
Market Watch17 November 2023 Sentiment: POSITIVE

Shares of Curis Inc. CRIS, +4.23% gained nearly 6% premarket on Friday after Truist Securities analysts initiated coverage of the cancer-focused biotech company with a buy rating.

Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript
Seeking Alpha02 November 2023 Sentiment: NEUTRAL

Curis, Inc. (NASDAQ:CRIS ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Conference Call Participants Yale Jen - Laidlaw & Co. Operator Good morning, and welcome to Curis' Third Quarter 2023 Business Update Call. All participants will be in a listen-only mode.

What type of business is Curis?

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

What sector is Curis in?

Curis is in the Healthcare sector

What industry is Curis in?

Curis is in the Biotechnology industry

What country is Curis from?

Curis is headquartered in United States

When did Curis go public?

Curis initial public offering (IPO) was on 01 August 2000

What is Curis website?

https://www.curis.com

Is Curis in the S&P 500?

No, Curis is not included in the S&P 500 index

Is Curis in the NASDAQ 100?

No, Curis is not included in the NASDAQ 100 index

Is Curis in the Dow Jones?

No, Curis is not included in the Dow Jones index

When was Curis the previous earnings report?

No data

When does Curis earnings report?

The next expected earnings date for Curis is 08 November 2024